CAR T-Cell Therapy in India
Get CAR T-Cell Therapy at internationally accredited (JCI/NABH) Indian hospitals at a fraction of Western costs, with end-to-end international patient support — visa, travel, stay, and follow-up care.
CAR T-Cell Therapy in UAE
CAR T-Cell Therapy at leading UAE hospitals in Dubai and Abu Dhabi — world-class care closer to home, visa-free entry for many nationalities, international specialists, and modern facilities.
Overview
CAR T-Cell Therapy (Chimeric Antigen Receptor T-Cell Therapy) is a groundbreaking, personalized immunotherapy that genetically engineers a patient's own T-lymphocytes to recognize and destroy cancer cells with precision unmatched by conventional chemotherapy or radiation. In landmark clinical trials, CAR T-Cell products such as axicabtagene ciloleucel (Yescarta) and tisagenlecleucel (Kymriah) have achieved complete remission rates of 40–54% in relapsed/refractory large B-cell lymphoma and up to 81% overall response rates in pediatric B-cell ALL. GAF Healthcare connects international patients with India's and the UAE's most advanced CAR T-Cell centers—offering JCI/NABH-accredited oncology programs, world-class apheresis infrastructure, and end-to-end logistics support at a fraction of Western costs.
Hospital Stay: 21–35 days (inpatient monitoring phase: apheresis, conditioning chemotherapy, infusion, and acute toxicity management) • Total Stay in Country (Fit-to-Fly): 8–14 weeks (minimum 60–90 days post-infusion before international air travel is considered safe, subject to treating physician clearance, ECHO, and full blood count recovery) • Success Rate: 40–81% (varies by indication: ~81% ORR in pediatric B-ALL; 52–83% ORR in DLBCL; 65–85% in multiple myeloma with newer BCMA-targeted constructs)
What Is It?
CAR T-Cell Therapy represents a paradigm shift in the treatment of hematological malignancies and is increasingly being explored in solid tumors. The process begins with leukapheresis—collecting a patient's T-lymphocytes from peripheral blood—which are then sent to a Good Manufacturing Practice (GMP)-certified laboratory where they are retrovirally or lentivirally transduced to express a chimeric antigen receptor on their surface. This receptor is engineered to bind a specific tumor antigen (most commonly CD19 for B-cell malignancies, BCMA for multiple myeloma, or CD22 as an emerging target) with high affinity, bypassing the need for MHC-mediated antigen presentation that cancer cells frequently downregulate to evade immunity.
Once the engineered cells have been expanded to therapeutic numbers (typically 10⁸–10⁹ cells over 2–4 weeks of manufacturing), the patient undergoes lymphodepletion chemotherapy—most commonly a fludarabine-cyclophosphamide regimen—to create immunological space that enhances CAR T-cell engraftment and persistence. The CAR T-cell product is then infused intravenously. The reinfused cells undergo robust in-vivo expansion, trafficking to tumor sites and initiating coordinated cytolytic activity. In responders, dramatic tumor regression can be observed within 1–4 weeks of infusion, and durable complete remissions lasting beyond 5 years have been documented in a subset of patients with diffuse large B-cell lymphoma (DLBCL) and B-cell ALL.
The current standard of care for CAR T-Cell Therapy is governed by FDA/EMA approvals and NCCN guidelines, with six CAR T-cell products approved globally as of 2024: tisagenlecleucel (Kymriah), axicabtagene ciloleucel (Yescarta), lisocabtagene maraleucel (Breyanzi), brexucabtagene autoleucel (Tecartus), idecabtagene vicleucel (Abecma), and ciltacabtagene autoleucel (Carvykti). Hospitals in India and the UAE offering CAR T-Cell programs are equipped with certified GMP facilities, dedicated CAR T-Cell infusion units, 24/7 critical care for cytokine release syndrome (CRS) management, and neurology support for immune effector cell-associated neurotoxicity syndrome (ICANS).
Candidates
• ELIGIBLE DIAGNOSES: Relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after ≥2 prior lines of systemic therapy; R/R follicular lymphoma (grade 3B); R/R mantle cell lymphoma; R/R B-cell acute lymphoblastic leukemia (B-ALL) in pediatric and young adult patients (up to age 25); R/R multiple myeloma after ≥4 prior lines (including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 antibody).
• PERFORMANCE STATUS: ECOG performance status 0–2; Karnofsky Performance Score ≥60%.
• ORGAN FUNCTION REQUIREMENTS (ELIGIBILITY THRESHOLD): Creatinine clearance ≥45 mL/min (CKD-EPI formula); ALT/AST ≤5× ULN; total bilirubin ≤2× ULN; LVEF ≥50% confirmed on 2D Echocardiography (ECHO) or MUGA scan; no active Grade ≥3 pulmonary dysfunction (baseline O₂ saturation ≥92% on room air).
• REQUIRED DIAGNOSTIC WORKUP BEFORE TRAVEL: Whole-body PET-CT scan (FDG) within 4 weeks; bilateral bone marrow biopsy with flow cytometry and cytogenetics; complete blood count with differential and comprehensive metabolic panel; serum protein electrophoresis and immunofixation (for myeloma); HLA typing (for allogeneic considerations); infectious disease panel (HIV Ag/Ab, Hepatitis B surface Ag and core Ab, Hepatitis C Ab, CMV IgG/IgM, EBV VCA IgG, quantitative CMV PCR); cardiac ECHO; pulmonary function tests (FEV1, DLCO); MRI brain (to rule out CNS disease or ICANS risk factors); prior treatment records including all chemotherapy regimens, radiation fields, stem cell transplant history.
• RELATIVE CONTRAINDICATIONS: Active, uncontrolled infection including active Hepatitis B replication (HBV DNA detectable); active CNS malignancy with mass lesion >1 cm (relative, not absolute); history of severe autoimmune disease requiring systemic immunosuppression; prior allogeneic HSCT within 6 months or active graft-versus-host disease (GVHD) on immunosuppression; active corticosteroid use (>10 mg prednisone/day equivalent) within 72 hours of infusion; pregnancy or lactation.
• ABSOLUTE CONTRAINDICATIONS: Prior CAR T-cell therapy targeting the same antigen with disease progression attributable to antigen loss; severe irreversible cardiac failure (LVEF <35%); uncontrolled grade 4 pulmonary dysfunction.
Procedure
CAR T-Cell Therapy is not a single procedure but a multi-step biological manufacturing and clinical delivery process. The following approaches and product categories are available at partner centers in India and the UAE:
1. AUTOLOGOUS CAR T-CELL THERAPY (CURRENT STANDARD): The patient's own T-cells are harvested, engineered, and reinfused. Products include FDA/EMA-approved tisagenlecleucel (lentiviral CD19-targeting), axicabtagene ciloleucel (retroviral, CD19), lisocabtagene maraleucel (lentiviral, CD19, defined 4-1BB co-stimulatory domain with a 1:1 CD4:CD8 ratio for reduced neurotoxicity risk), brexucabtagene autoleucel (retroviral, CD19, specifically approved for mantle cell lymphoma), and BCMA-targeting constructs idecabtagene vicleucel and ciltacabtagene autoleucel for multiple myeloma. Manufacturing turnaround time ranges from 17 to 22 days for most commercial products.
2. LOCALLY MANUFACTURED / ACADEMIC CAR T-CELL PROGRAMS (INDIA-SPECIFIC): Several institutions in India—including Tata Memorial Centre (Mumbai), AIIMS (New Delhi), and Christian Medical College (Vellore)—have established indigenous CAR T-Cell manufacturing programs under the Central Drugs Standard Control Organisation (CDSCO) regulatory framework. India's first indigenously developed CD19 CAR T-Cell product (developed collaboratively by ACTREC and IIT Bombay) received CDSCO approval in 2023, at a significantly reduced cost compared to imported commercial products ($40,000–$70,000 vs. $350,000+ in Western markets). This is a critical cost advantage for international patients.
3. DUAL-ANTIGEN / BISPECIFIC CAR T-CELL CONSTRUCTS (INVESTIGATIONAL / CLINICAL TRIALS): Available at select academic centers; constructs targeting CD19/CD22 simultaneously are designed to overcome antigen escape—a primary mechanism of relapse after single-antigen CD19 CAR T-Cell therapy. Patients who have failed prior CD19 CAR T-Cell treatment may be eligible.
4. ALLOGENEIC (OFF-THE-SHELF) CAR T-CELL THERAPY: Using donor-derived T-cells (allogeneic) with additional gene edits to reduce graft-versus-host potential. Still predominantly investigational (Phase I/II trials); available at select centers in the UAE (e.g., Cleveland Clinic Abu Dhabi's oncology program). Offers faster availability without the manufacturing delay inherent to autologous collection.
5. LYMPHODEPLETION REGIMEN SELECTION: The standard fludarabine (30 mg/m² × 3 days) + cyclophosphamide (500 mg/m² × 3 days) regimen is used most commonly. Bendamustine-based lymphodepletion is an alternative for patients with fludarabine intolerance (e.g., significant renal impairment). The conditioning regimen profoundly influences CAR T-cell expansion kinetics and clinical response.
6. TOXICITY MANAGEMENT TECHNOLOGIES: All partner centers utilize the ASTCT 2019 CRS and ICANS grading consensus criteria. Management protocols include tocilizumab (anti-IL-6R) as first-line CRS intervention, corticosteroids for Grade ≥2 ICANS, and siltuximab as a second-line agent. Continuous EEG monitoring is available for high-risk ICANS patients. Ferritin, IL-6, CRP, and D-dimer are monitored daily during the acute post-infusion phase as biomarkers of CRS severity and hemophagocytic lymphohistiocytosis (HLH) risk.
Cost of CAR T-Cell Therapy: India vs. UAE
CAR T-Cell Therapy is among the most expensive cancer treatments globally, with commercial products in the United States and Western Europe priced at $370,000–$475,000 for the cell therapy product alone, before hospital and physician fees. India and the UAE offer dramatically more accessible pricing—particularly India, where indigenously manufactured CD19 CAR T-Cell products have transformed affordability without compromising clinical outcomes. The table below reflects all-inclusive estimates (cell manufacturing, lymphodepletion chemotherapy, inpatient stay, toxicity management including tocilizumab, and standard follow-up visits to Day 60). International patients should note that commercial imported products (Kymriah, Yescarta) cost significantly more even in India and the UAE than domestically manufactured alternatives, and GAF Healthcare's case managers will advise on the most clinically appropriate and cost-effective product for each patient's diagnosis.
| Destination | Estimated Cost (USD) | Key Advantage |
|---|---|---|
| India | $40,000 – $100,000 | ~48% less than the UAE |
| UAE (Dubai/Abu Dhabi) | $90,000 – $180,000 | Premium care, JCI/DHA accredited |
Estimates typically include surgery, hospital stay, and standard medications. Contact us for a personalised quote.
Recovery & Aftercare
PHASE 1 — PRE-TRAVEL CONSULTATION (2–4 weeks before departure):
• Upload complete medical records, PET-CT, bone marrow biopsy, and prior treatment summaries to GAF Healthcare's secure patient portal.
• GAF's oncology case managers facilitate a teleconsultation with the destination center's CAR T-Cell specialist within 48–72 hours.
• Treatment eligibility is confirmed; manufacturing slot is reserved with the CAR T-Cell program.
• India: e-Medical Visa (e-MV) application assisted by GAF (processing 3–5 business days). UAE: Visa-on-arrival or visa waiver available for 50+ nationalities; GAF assists with medical invitation letter for others.
PHASE 2 — ARRIVAL & PRE-TREATMENT WORKUP (Days 1–5 in country):
• Airport-to-hospital transfer via GAF's dedicated medical transport.
• Comprehensive baseline evaluation: repeat PET-CT (if >4 weeks since last scan), ECHO, pulmonary function tests, CNS MRI, infectious disease re-screening, and a multidisciplinary team (MDT) review involving hematological oncology, critical care, neurology, and pharmacy.
• Bridging chemotherapy may be administered during this phase if disease is rapidly progressing or if manufacturing time exceeds 3 weeks.
PHASE 3 — LEUKAPHERESIS (Day 5–7):
• Outpatient or inpatient apheresis procedure (3–5 hours) via a large-bore peripheral IV or apheresis catheter. T-lymphocytes are collected and cryopreserved.
• Product is shipped under controlled cryogenic conditions (-196°C liquid nitrogen) to the GMP manufacturing facility (domestic or international, depending on the product selected).
• Patient may return to GAF-arranged accommodation or remain hospitalized for bridging therapy during the manufacturing period (17–22 days for commercial products; 4–6 weeks for some academic products).
PHASE 4 — BRIDGING THERAPY & MONITORING (Days 7–28 approximately):
• Low-intensity bridging chemotherapy (e.g., polatuzumab vedotin-based, bendamustine-rituximab, or steroid-based regimens) to control disease burden without compromising T-cell collection viability.
• Serial CBC monitoring and clinical assessment.
• Patient and one designated caregiver/attendant are housed in GAF-arranged serviced apartments or hospital guest houses within 15 minutes of the treatment center.
PHASE 5 — LYMPHODEPLETION CHEMOTHERAPY (Days -5 to -1 relative to infusion):
• Hospital admission.
• Fludarabine + cyclophosphamide administered intravenously over 3 consecutive days.
• Anti-emesis, hydration, and mesna uroprotection protocols initiated.
• Baseline cytokine panel drawn (IL-6, ferritin, fibrinogen, CRP, LDH).
PHASE 6 — CAR T-CELL INFUSION (Day 0):
• Cryopreserved CAR T-cell product is thawed and administered intravenously in the dedicated CAR T infusion suite (HEPA-filtered positive or negative pressure room depending on protocol).
• Infusion duration: 15–60 minutes depending on product and volume.
• Vitals, oxygen saturation, and neurological status monitored continuously for 2 hours post-infusion, then every 4 hours for 48 hours.
PHASE 7 — ACUTE MONITORING (Days 1–14 post-infusion, mandatory inpatient):
• CRS onset typically Day 1–7: fever, hypotension, hypoxia managed with tocilizumab ±corticosteroids per institutional protocol.
• ICANS onset typically Day 5–10: neurocognitive assessment using CARTOX-10 score or ICE score twice daily; EEG if score drops ≤7.
• Daily labs: CBC, CMP, LFTs, coagulation panel, ferritin, IL-6, CRP, fibrinogen, D-dimer, and quantitative CAR T-cell expansion by peripheral blood flow cytometry or qPCR.
• MILESTONE: Safe hospital discharge typically occurs Day 10–21 if CRS resolves to Grade ≤1 and ICANS resolves to Grade ≤1.
PHASE 8 — OUTPATIENT RECOVERY (Days 15–60 post-infusion):
• Mandatory outpatient clinic visits: twice weekly for the first 4 weeks, then weekly through Day 60.
• Monitoring for late CRS, prolonged cytopenia (B-cell aplasia, neutropenia), hypogammaglobulinemia (requiring IVIG supplementation), and secondary HLH.
• Infectious prophylaxis: acyclovir (HSV/VZV), fluconazole or posaconazole (fungal), and PCP prophylaxis (trimethoprim-sulfamethoxazole or pentamidine).
• CAR T-cell persistence measured at Day 28, Day 60, and Day 90.
PHASE 9 — RESPONSE ASSESSMENT & FIT-TO-FLY CLEARANCE (Week 8–14):
• PET-CT response assessment at Day 28–30 and Day 90 per Lugano 2014 criteria.
• Treating physician issues fit-to-fly certificate when: ANC >1,000/μL sustained, platelet count >50,000/μL, no active CRS/ICANS, no supplemental oxygen requirement, and ECHO confirms preserved LVEF.
• Most patients are cleared for international travel between 8 and 14 weeks post-infusion; some with protracted cytopenias or hypogammaglobulinemia may require 16 weeks.
• GAF Healthcare coordinates the discharge summary, digital medical records transfer, and teleconsultation scheduling with the patient's home oncologist.
Risks & Considerations
CAR T-Cell Therapy carries a distinct and serious toxicity profile that patients and caregivers must understand thoroughly before initiating treatment. Cytokine Release Syndrome (CRS) is the most common acute toxicity, occurring in 57–93% of patients depending on the product and disease burden; Grade 3–4 CRS (severe hypotension, Grade 3+ hypoxia requiring high-flow oxygen or mechanical ventilation) occurs in 13–22% of cases and requires ICU-level management including vasopressors and tocilizumab. Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) occurs in 20–60% of patients, presenting as confusion, aphasia, tremor, and in severe cases (Grade 4), seizures, cerebral edema, and rarely death; the mortality risk from Grade 4 ICANS is approximately 1–3%. Prolonged and severe cytopenias (neutropenia, anemia, thrombocytopenia) lasting beyond 30 days occur in 30–40% of patients and substantially increase infection risk; febrile neutropenia requires prompt hospitalization and broad-spectrum antibiotics. B-cell aplasia is an expected on-target off-tumor effect of CD19 CAR T-Cell products and leads to hypogammaglobulinemia requiring monthly IVIG infusions, sometimes for 12–24 months post-treatment. Hemophagocytic lymphohistiocytosis (HLH) is a rare (2–5%) but life-threatening hyperinflammatory complication associated with a mortality rate of 30–50% if not recognized promptly; it is characterized by hyperferritinemia (>10,000 ng/mL), cytopenias, and liver dysfunction. Tumor lysis syndrome (TLS) can occur in the context of rapid disease response, particularly in high-burden lymphoma, and requires aggressive pre-infusion hydration and urate-lowering therapy (allopurinol or rasburicase). Late-onset infections—particularly with encapsulated bacteria, CMV reactivation, and opportunistic fungi—remain a risk during the 6–12 months of immune reconstitution. Disease relapse, occurring in 30–60% of responders within 2 years, may be mediated by antigen loss (CD19 downregulation), T-cell exhaustion, or immunosuppressive tumor microenvironment, and may require subsequent therapy. All patients must have a dedicated caregiver present 24 hours per day during the mandatory inpatient and early outpatient phases. Travel insurance must specifically cover CAR T-Cell-related complications; GAF Healthcare's partner insurance advisors assist with policy identification.
Top Hospitals for CAR T-Cell Therapy
The following JCI and NABH-accredited hospitals are among the most experienced in specialist care, with dedicated teams and high-volume programmes.
Apollo Hospitals
New Delhi, India
Medanta - The Medicity
Gurgaon, India
Kokilaben Dhirubhai Ambani Hospital
Mumbai, India
Tata Memorial Hospital
Mumbai, India
Top Doctors for CAR T-Cell Therapy
Internationally trained specialists in Cancer Care. Review their profiles, compare experience, and connect directly through GAF Healthcare.
Dr. Vinod Raina
MBBS, MD (Internal Medicine), DM (Medical Oncology), Fellowship, Fellowship
Medical Oncologist
Fortis Memorial Research Institute, Gurgaon, India
40+ Yearsof experience
Dr. Vinod Raina is a distinguished figure in the field of Medical Oncology in India, with over 40 years of exemplary experience. He is currently associated with Fortis Memorial Research Institute in Gurugram, where he functions as the Chairman and Head of Medical Oncology and Hematology. His primary expertise lies in chemotherapy treatment and he was the first to perform high-dose chemotherapy in India. He also performed the first peripheral blood BMT in… Read more
Dr. Kanchan Kaur
MBBS, MS (General Surgery), MRCS
Surgical Oncologist (Breast)
Medanta - The Medicity, Gurgaon, India
22+ Yearsof experience
Dr. Kanchan Kaur is a senior breast cancer and general surgeon who serves as Senior Director — Breast Cancer at the Cancer Care division of Medanta – The Medicity, Gurgaon. With more than two decades of surgical experience, she has built a multidisciplinary breast practice that combines oncologic clarity with deep patient empathy. Dr. Kanchan is widely respected for her work in breast cancer awareness and early detection. She works closely with several… Read more
Dr. Ashwin Sunil Tamhankar
MBBS, MS, MCh Urology, DNB Urology, Vattikuti Robotic Uro-oncology Fellowship, RCS Laser Urological Robotic Fellowship, Olympus Laparoscopic Endo-Urology Fellowship
Surgical Oncologist & Robotic Uro-Oncologist
Apollo Hospitals, Navi Mumbai, Mumbai, India
9+ Yearsof experience
Dr. Ashwin Sunil Tamhankar is a Consultant in Surgical Oncology and Robotic Surgery based at Apollo Hospitals in Navi Mumbai, India. With over 9 years of specialized experience, he has established himself as a leading uro-oncologist, combining advanced robotic surgical techniques with precision cancer care. His credentials include MBBS, MS, MCh Urology, DNB Urology, and prestigious fellowships from the Vattikuti Institute, Royal College of Surgeons of… Read more
Dr. Asit Arora
MBBS, MS, MCh
GI & HPB Surgical Oncologist
Indraprastha Apollo Hospital, New Delhi, India
22+ Yearsof experience
Dr. Asit Arora is a Clinical Lead in GI and HPB Surgical Oncology at Indraprastha Apollo Hospital, New Delhi, bringing over 22 years of specialized expertise in managing complex gastrointestinal and hepatobiliary cancers. He holds an MBBS, MS in General Surgery, and an MCh in Gastrointestinal Surgery, and is widely recognized across India and internationally for his precision in radical oncologic resections and advanced abdominal cancer surgery. Dr. Arora… Read more
Dr. B. Niranjan Naik
MBBS, MS, Onco-Surgery, FIAGES
Surgical Oncologist
Paras Hospitals, Gurugram, India
22+ Yearsof experience
Dr. B. Niranjan Naik is Principal Director of Surgical Oncology and Director of Breast & Gastro-Intestinal Onco-Surgery at Paras Hospitals in Gurugram. With over 22 years of distinguished clinical experience, he is widely recognized as one of the leading breast cancer surgeons in the Delhi and Gurugram region. His credentials include MBBS and MS (General Surgery) from the All India Institute of Medical Sciences (AIIMS), New Delhi, followed by specialized… Read more
Frequently Asked Questions — CAR T-Cell Therapy
The all-inclusive cost of CAR T-Cell Therapy in India ranges from approximately $40,000 to $100,000 USD—making it one of the most cost-effective destinations globally for this treatment. This range covers leukapheresis, GMP-certified cell manufacturing (including India's indigenously approved CD19 CAR T-Cell product, which is significantly less expensive than imported commercial products like Kymriah or Yescarta), lymphodepletion chemotherapy, the inpatient hospital stay during infusion and acute toxicity management, tocilizumab administration for CRS treatment, standard outpatient follow-up visits through Day 60, and nursing care. In the UAE (Dubai or Abu Dhabi), the equivalent all-inclusive treatment cost ranges from approximately $90,000 to $180,000 USD—reflecting the use of internationally imported FDA/EMA-approved commercial CAR T-cell products, premium inpatient infrastructure, and the UAE's higher overall healthcare operational costs. By comparison, the same treatment in the United States costs $450,000–$700,000+ when hospital, physician, and product fees are combined. GAF Healthcare's case managers provide a detailed, itemized cost estimate specific to each patient's diagnosis, selected product, and clinical risk profile before any financial commitment is made.
International patients undergoing CAR T-Cell Therapy must plan for a minimum stay of 8 to 14 weeks (approximately 60–100 days) in the treatment country before they are medically cleared for international air travel. This extended stay is a non-negotiable medical requirement, not a logistical preference. The mandatory post-infusion monitoring period is driven by several critical clinical factors: Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) can onset or escalate up to 14 days post-infusion and require immediate hospital-level intervention. Prolonged cytopenias (low neutrophil and platelet counts) typically persist for 4–8 weeks and represent a serious infection and bleeding risk during long-haul flights and in transit. Response assessment PET-CT scans are performed at Day 28–30 and Day 90 per international Lugano criteria, and treating physicians require at least the Day 28 scan before making a fit-to-fly determination. Blood counts, ECHO confirmation of cardiac function, and absence of active infection must all be verified before travel clearance is issued. Patients with severe or prolonged cytopenias, hypogammaglobulinemia requiring IVIG infusions, or delayed ICANS resolution may require up to 16 weeks before travel is safe. GAF Healthcare arranges comfortable serviced apartment accommodation for the patient and one attendant for the full duration of the stay, at pre-negotiated rates in close proximity to the treatment hospital.
The success rate of CAR T-Cell Therapy varies significantly by the specific cancer diagnosis, the patient's prior treatment history, and the CAR T-cell product used. In relapsed/refractory diffuse large B-cell lymphoma (DLBCL)—the most common indication—axicabtagene ciloleucel (Yescarta) achieves an overall response rate (ORR) of 72–83% and a complete response (CR) rate of 52–58%, with approximately 40% of patients maintaining durable CR beyond 2 years (considered functionally curative). Lisocabtagene maraleucel (Breyanzi) demonstrates similar efficacy with a more favorable toxicity profile (lower Grade ≥3 ICANS rates). In pediatric and young adult B-cell Acute Lymphoblastic Leukemia (B-ALL), tisagenlecleucel (Kymriah) achieves an ORR of 81% with 60% complete remission at 12 months—remarkable outcomes in a population with otherwise limited options. In relapsed/refractory multiple myeloma, ciltacabtagene autoleucel (Carvykti) achieves an ORR of 97% with a 78% stringent complete response rate in heavily pre-treated patients, though long-term follow-up data are still maturing. For follicular lymphoma, axicabtagene ciloleucel achieves an ORR of 94% and CR of 79%. It is important to understand that 'success' in CAR T-Cell Therapy encompasses complete response rates, progression-free survival, and durable remission—not all responders achieve cure, and disease relapse, often via antigen escape, occurs in 30–60% of initial responders within 2 years. GAF Healthcare's partner oncologists provide individualized prognosis estimates based on the patient's specific pathology, molecular markers, prior therapy lines, and performance status before treatment initiation.
Why Plan Your Treatment Through Gaf Healthcare?
GAF Healthcare provides a fully integrated, end-to-end logistics infrastructure designed specifically for the complexity of CAR T-Cell therapy, where timing, proximity to the treatment center, and rapid access to emergency care during the post-infusion monitoring period are non-negotiable.
VISA ASSISTANCE — INDIA: GAF Healthcare's visa coordination team assists patients with the Indian e-Medical Visa (e-MV) application, which permits a stay of up to 60 days per entry (extendable to 180 days for treatment requiring prolonged stay). The e-MV is typically processed within 3–5 business days upon submission of a medical invitation letter from the treating hospital—which GAF secures on the patient's behalf. One accompanying attendant is eligible for an e-Medical Attendant Visa simultaneously. VISA ASSISTANCE — UAE: Citizens of 50+ countries benefit from visa-on-arrival (30–90 days) or visa-free entry to the UAE. Nationals of countries requiring advance visas are supported with GAF's medical visit visa application service, including a formal invitation letter from the UAE-accredited hospital and medical documentation packet.
AIRPORT & INTER-CITY TRANSFERS: GAF arranges compliant medical transport from the airport to the treatment center—standard saloon vehicles for ambulatory patients and fully equipped medical transport vans (with stretcher capability and an attending nurse) for patients with compromised ECOG status. All transfers in India and the UAE are coordinated in real time and scheduled around flight arrivals to minimize patient fatigue.
ACCOMMODATION FOR PATIENT AND ATTENDANT: Given the 8–14-week required stay, GAF Healthcare negotiates extended-stay serviced apartment packages located within a 10–15-minute drive of partner hospitals in Mumbai, New Delhi, Chennai, Hyderabad (India), and Dubai, Abu Dhabi (UAE). Accommodation includes hospital-grade hygiene protocols (HEPA air filtration available on request for immunocompromised patients), laundry, daily housekeeping, and 24-hour security. Costs range from $40–$90 per night in India and $100–$200 per night in the UAE, significantly below comparable hotel rates.
DEDICATED CASE MANAGER & TRANSLATORS: Each patient is assigned a dedicated GAF Healthcare case manager who serves as a single point of contact from initial inquiry through post-discharge. The case manager coordinates appointment scheduling, lab result communication, pharmacy procurement, and emergency escalation. Language interpretation services are available in Arabic, Russian, French, Swahili, Uzbek, Kazakh, and 12 other languages—provided either in-person at the hospital or via a certified medical interpreter on video call for consultations.
REMOTE MONITORING SUPPORT & TELECONSULTATION: After returning home, GAF Healthcare facilitates structured teleconsultation follow-ups at Day 90, Day 180, and Month 12 with the treating CAR T-Cell oncologist. Lab results from the patient's local facility can be uploaded to the GAF digital health portal and reviewed remotely. Emergency escalation protocols are in place 24/7 for patients who develop late-onset CRS, ICANS, or infection within 6 months of returning home.
Patients Also Explore
Other treatments commonly sought by patients considering CAR T-Cell Therapy.
Cryosurgery
Surgical Oncology
Robotic Surgery
Surgical Oncology
Anemia
Hematology
Leukemia Treatment
Hematology